High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$10.6M
$10,585,690
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
ELVN
S
Enliven Therapeutics, Inc.
Collins Helen Louise
• Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -28.8%
2026-03-10
$305,827
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -28.8%
|
2026-03-10 | $305,827 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Collins Helen Louise
• Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -54.4%
2026-03-09
$896,811
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -54.4%
|
2026-03-09 | $896,811 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Hohl Benjamin
• CFO
Discretionary SellΔOwn -16.4%
2026-03-06
$295,839
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
CFO
Discretionary SellΔOwn -16.4%
|
2026-03-06 | $295,839 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Collins Helen Louise
• Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -64.3%
2026-02-17
$1,177,862Large
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -64.3%
|
2026-02-17 | $1,177,862Large | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
Director
10b5-1 Sell
|
2026-02-17 | $32,196 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Lyssikatos Joseph P
• Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
2026-02-06
$145,219
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
|
2026-02-06 | $145,219 | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
Director
10b5-1 Sell
|
2026-01-20 | $32,902x2 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Lyssikatos Joseph P
• Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
2026-01-20
$535,099x2
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
|
2026-01-20 | $535,099x2 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Heyman Richard A.
• Director
10b5-1 SellΔOwn -14.6%
2026-01-09
$107,125
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Director
10b5-1 SellΔOwn -14.6%
|
2026-01-09 | $107,125 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Lyssikatos Joseph P
• Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
2026-01-09
$2,482,578Largex2
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
|
2026-01-09 | $2,482,578Largex2 | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
COO
10b5-1 Sell
|
2026-01-09 | $1,351,762Largex2 | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
Director
10b5-1 Sell
|
2026-01-08 | $241,156x2 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Lyssikatos Joseph P
• Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
2026-01-08
$993,436x2
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
|
2026-01-08 | $993,436x2 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Lyssikatos Joseph P
• Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
2025-12-19
$84,206
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
|
2025-12-19 | $84,206 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Lyssikatos Joseph P
• Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
2025-11-19
$279,155x2
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
|
2025-11-19 | $279,155x2 | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2025-11-17 | $272,739 | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
COO
10b5-1 Sell
|
2025-11-07 | $116,034x2 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Lyssikatos Joseph P
• Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
2025-10-20
$276,025
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
|
2025-10-20 | $276,025 | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2025-10-17 | $266,654 | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
COO
10b5-1 Sell
|
2025-10-07 | $133,993 | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
CFO
10b5-1 SellΔOwn -12.4%
|
2025-09-29 | $66,291 | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2025-09-26 | $74,228 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Lyssikatos Joseph P
• Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
2025-09-26
$81,005
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
|
2025-09-26 | $81,005 | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2025-09-23 | $56,084 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Lyssikatos Joseph P
• Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
2025-09-23
$30,045
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
|
2025-09-23 | $30,045 | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2025-09-19 | $20,250 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Lyssikatos Joseph P
• Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
2025-09-19
$135,697x2
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF SCIENTIFIC OFFICER
10b5-1 Sell
|
2025-09-19 | $135,697x2 | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2025-09-17 | $95,473 | S | Form 4 |